table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
Immunostimulants drugs
convalescent plasma treatment CONV-ERT CoV-Early ... C3PO
Early convalescent plasma. CoV-Early ...
interferon
inhaled interferon
SNG001 inhaled interferon beta ACTIV-2 SNG001
peginterferon Feld TOGETHER interferon lambda
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...
bamlanivimab monotherapy BLAZE-1 phase 2 ... OPTIMISE-C19 ...
bamlanivimab/etesevimab BLAZE-4 BLAZE-1 phase 2 ... BLAZE-1 phase 3 ... OPTIMISE-C19 ...
Bebtelovimab (LY-CoV1404) BLAZE 4 LY-CoV1404
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Mazzotta Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) TACKLE
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 2 CT-P59 3.2 part 1
sotrovimab (Xevudy; VIR-7831) COMET-ICE

1 studies excluded by filtering options 1

6708 Webb, 2021 0130selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons